home / stock / inkt / inkt quote
Last: | $0.9014 |
---|---|
Change Percent: | 0.0% |
Open: | $0.89 |
Close: | $0.9014 |
High: | $0.9227 |
Low: | $0.89 |
Volume: | 6,844 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.9014 | $0.89 | $0.9014 | $0.9227 | $0.89 | 6,844 | 07-03-2024 |
$0.89 | $0.9398 | $0.89 | $0.9498 | $0.885 | 19,884 | 07-02-2024 |
$0.9159 | $0.9499 | $0.9159 | $0.95 | $0.89 | 32,493 | 07-01-2024 |
$0.9492 | $0.9291 | $0.9492 | $0.9492 | $0.905 | 38,238 | 06-28-2024 |
$0.93 | $0.9 | $0.93 | $0.93 | $0.884557 | 31,147 | 06-27-2024 |
$0.89 | $0.8901 | $0.89 | $0.925 | $0.8838 | 21,465 | 06-26-2024 |
$0.89 | $0.91 | $0.89 | $0.93 | $0.89 | 36,043 | 06-25-2024 |
$0.9 | $0.95 | $0.9 | $0.95 | $0.87 | 57,904 | 06-24-2024 |
$0.9148 | $0.89 | $0.9148 | $0.915 | $0.87 | 50,302 | 06-21-2024 |
$0.8701 | $0.88 | $0.8701 | $0.9 | $0.8701 | 32,261 | 06-20-2024 |
$0.8771 | $0.91 | $0.8771 | $0.9275 | $0.8771 | 56,343 | 06-19-2024 |
$0.8771 | $0.91 | $0.8771 | $0.9275 | $0.8771 | 56,343 | 06-18-2024 |
$0.91 | $0.91 | $0.91 | $0.948 | $0.9 | 32,996 | 06-17-2024 |
$0.9197 | $0.97 | $0.9197 | $0.98 | $0.902 | 55,880 | 06-14-2024 |
$0.9658 | $0.961 | $0.9658 | $0.9817 | $0.957 | 16,391 | 06-13-2024 |
$0.9642 | $0.99 | $0.9642 | $1.01 | $0.9513 | 33,076 | 06-12-2024 |
$0.99 | $0.98 | $0.99 | $0.9996 | $0.951001 | 12,577 | 06-11-2024 |
$0.952 | $1.01 | $0.952 | $1.01 | $0.9512 | 36,241 | 06-10-2024 |
$0.96425 | $0.96 | $0.96425 | $0.9957 | $0.95 | 45,976 | 06-07-2024 |
$0.98 | $0.99 | $0.98 | $1 | $0.961 | 40,825 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
MiNK Therapeutics Inc. Company Name:
INKT Stock Symbol:
NASDAQ Market:
MiNK Therapeutics Inc. Website:
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immun...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models...